Market Insight- Middle East Tapentadol Market
Market Overview
Tapentadol is a type of opioid analgesic, prescribed for severe pain management on routine basis or around the clock for treatment or long-term opioid treatment. The substitute options for this are not efficient. Tapentadol is also prescribed for neuropathic pain related to diabetic peripheral neuropath. The most common application is in the management chronic, acute, and cancer-associated pain. Nucynata ER is the first and only U.S. Food and Drug Administration (FDA)-approved long-acting opioid analgesic, which is designed to treat neuropathic pain and nociceptive pain related to diabetic peripheral neuropathy. Outside the U.S., nucynata is available as Palexia.
Furthermore, Nucynta ER is contraindicated for patients suffering from significant respiratory depression, known or suspected gastrointestinal obstruction, acute or severe bronchial asthma or hypercarbia, including paralytic ileus, concurrent use of monoamine oxidase inhibitors (MAOIs), and Hypersensitivity (e.g. anaphylaxis, angioedema) to tapentadol or to any other ingredients of the product or use of MAOIs within a period of 14 days.
Request Here Free Sample Copy Report
Market Drivers
Growing cases of cancer and diabetic neuropathy across the Middle East is expected to drive growth of the Middle East tapentadol market during the forecast period. According to data published in World Journal of Diabetes in 2016, the Middle Eastern and North African regions are estimated to have the second-highest rate of diabetes in the world. In Arab World, the prevalence of diabetes is projected to increase to 96.2% by 2035, as estimated by World Journal of Diabetes in 2016. Furthermore, the World Health Organization (WHO) estimated that in the Eastern Mediterranean region, including Middle East, recorded 555,318 new cases of cancer in 2012, which is projected to rise to 961,098 by 2030. Therefore, there a major increase in cancer cases across Eastern Mediterranean region.
The Middle East tapentadol market was valued at US$ 0.82 million in 2016 and is expected to witness a robust CAGR of 6.1% over the forecast period (2017-2025).
Unavailability of gold standard opioid therapy for neuropathic pain other than tapentadol is expected to propel the Middle East tapentadol market growth over the forecast period.
Generally, neuropathic pain is caused due to dysfunction of or lesion to peripheral or central nervous system and is chronic in nature with a critical pathophysiology. Nucynta ER is typically used in the treatment of neuropathic. There is low quality evidence that the oral tramadol has any important beneficial effect on pain for people suffering from severe or moderate neuropathic pain, whereas the main indication of tapentadol is to treat the diabetic neuropathic pain. This proves that other opioids such as fentanyl, oxycodone, tramadol, and oxymorphone are not as effective as tapentadol in the treatment of neuropathic pain.
Competitive Section
Key companies operating in the Middle East tapentadol market are Depomed, Inc., Janssen Pharmaceutical, Inc., Grünenthal, and Allergan Plc.
Table of Contents
- Research Objective and Assumption
- Research Objectives
- Assumptions
- Abbreviations
- Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Therapeutic Application
- Market Snippet, By Countries
- Coherent Opportunity Map (COM)
- Report Description
- Market Dynamics, Regulations, and Trends Analysis
- History Of Tapentadol
- Comparison with substitute
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- PEST Analysis
- Impact Analysis
- Industry Trend
- Epidemiology
- PORTER’s Five Forces Analysis
- Ongoing Clinical Trials
- Regulatory Scenario
- Reimbursement Policies
- Middle East Tapentadol Market, By Therapeutic Application, 2015 – 2025, (US$ Million)
- Introduction
- Market Share Analysis, 2017 and 2025 (%)
- Y-o-Y Growth Analysis, 2016 – 2025
- Pain Management
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2015 – 2025, (US$ Million)
- Neuropathic Pain
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2015 – 2025, (US$ Million)
- Cancer Pain
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2015 – 2025, (US$ Million)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2015 – 2025, (US$ Million)
- Neuropathic Pain
- Cough Treatment
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2015 – 2025, (US$ Million)
- Introduction
- Middle East Tapentadol Market, By Countries, 2015 – 2025 (US$ Million)
- Introduction
- Market Share Analysis, 2017 and 2025 (%)
- Y-o-Y Growth Analysis, 2016 – 2025
- Region Trends
- Market Size and Forecast, By Country, 2017 and 2025 (%)
- KSA
- Country Trends *
- Market Size and Forecast (US$ Million)
- UAE
- Bahrain
- Oman
- Qatar
- Israel
- Iran
- KSA
- Introduction
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
Contact Us:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837